Evotec SE (EVT.DE)
| Previous Close | 8.65 |
| Open | 8.78 |
| Bid | 8.94 x 105300 |
| Ask | 8.94 x 169300 |
| Day's Range | 8.66 - 9.03 |
| 52 Week Range | 8.27 - 24.44 |
| Volume | |
| Avg. Volume | 1,589,087 |
| Market Cap | 1.601B |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings Date | Aug 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
ACCESSWIREEvotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics ...
- ACCESSWIRE
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease
Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's disease One of Evotec's largest strategic drug discovery alliances HAMBURG, GERMANY / ACCESSWIRE / May 28, 2024 / Evotec SE (Frankfurt Stock Exchange: ...
- ACCESSWIRE
Evotec Reports Q1 2024 Results and Provides Corporate Update
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER STRONG START WITH JUST - EVOTEC BIOLOGICS IN Q1 2024 POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY ...
